MorphoSys AG — Investor Presentation 2011

May 23, 2011

Bio€q y uit Europe 2011

Paris – May 23, 2011

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions regulatory reforms foreign exchange rate fluctuations and the conditions, reforms, the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Morp y hoS s at a Glance

Industry y 's most successful antibody library technology - HuCAL

74 drug programs ongoing

P fit bl t b l h t Profitable, strong balance sheet

Use proprietary technologies to develop the broadest possible pipeline of therapeutic antibody drugs,

balanced between partnered and proprietary programs

Growing p Pi eline Illustrates Successful Execution of Strategy

Clinical Total

Uniq p y gy ue & Proprietary Technology for Generating Drug-Quality Antibodies

74 Therap y g gg eutic Antibody Programs Ongoing: 18 Programs in Clinical Trials

n.d. not disclosed IPF: Idiopathic Pulmonary Fibrosis ADC: Antibody Drug Conjugate

Current Pipeline Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

MOR103A Novel Anti-Inflammatory Antibody

The Target

GM-CSF – a growth factor and inflammatory mediator

The Drug

Ultra-high affinity HuCAL IgG1

Clinical Development in Rheumatoid Arthritis

• Phase 1b/2a trial ongoing in Europe in patients with active RA
• Completion of enrollment H2 2011 final results H1 2012 2011,

Clinical Development in Multiple Sclerosis

Phase 1b safety study in MS patients starting H2 2011

Intellectual Property

• Exclusive license to a US patent covering antibodies against GM-CSF for the treatment of chronic inflammatory conditions
• US patent on MOR103 composition of matter

Comp g pp p elling New Data Support Multiple Sclerosis as Second Indication for MOR103

Codarri et al., Nature Immunology, March 2011

GM-CSF has ^a non CSF non-redundant role in the development of ^a mouse model redundant of multiple sclerosis

Abundant Other Evidence

• Elevated levels of GM-CSF correlate with active phase of multiple sclerosis
• GM-CSF knock-out mice do not develop neuro-inflammation
• MOR103 reduces neuro-inflammation score in rats inflammation

Unmet Medical Need

Still high unmet medical need, especially in progressive forms of disease

MOR208A Novel Anti-Cancer Antibody

The Target

CD19 – a pan B-cell marker p ³⁰ Namalwa

The Drug

• Humanized, high affinity anti-CD19 antibody
• Exclusive license from Xencor
• Comprises a proprietary Xencor modification that leads to rapid and sustained B-cell depletion

Clinical Development in Chronic Lymphocytic Leukemia

• Multi-centre, open-label, multi-dose, single-arm phase 1, dose-escalation study in USA Lymphoma
• Patients with chronic lymphocytic leukemia, who have not responded to or have become refractory to previous therapies
• Xencor funds phase 1 trial from \$13m up front payment up-front
• Final data expected in 2012

MOR208

XmAb (-) control

Alemtuzumab (CD52)

MOR202A Novel Antibody for Multiple Myeloma

The Target

CD38 – ^a protein on multiple myeloma cells

The Drug

• Higy y h affinity HuCAL antibody
• Excellent cross-reactivity to non-human primate (tox)

Clinical Development in Multiple Myeloma

• Start multi-centre, open-label, dose-escalation study in Europe H1 2011
• Patients with relapsed/refractory multiple myeloma; failure of at least 2 prior therapies
• Maximum tolerated dose, safety and tolerability, pharmacokinetics and immunogenicity; assessment of preliminary activity
• Final data expected in 2013

AbD Serotec Seg p ment Complements Therapeutic Business

Antibodies for research and diagnostic markets

Diagnostic Antibodies

• Using proprietary technologies to deliver superior Dx antibodies
• Future upside via royalties

Research Antibodies

• Catalogue of 15,000+ products & custom HuCAL antibodies
• Stable and recurring cash flows

E U R i l l i m o n s	G i d 2 0 1 1 u a n c e	2 0 1 0
S S A b D R t t e r o e c e g m e n e e n e s v u	2 2 2 3 -	2 0 2.
S A b D P f i M i t t e r o e c r o a r g n	4 % ~	6 %

P&L d G id 2011 P&L an uidance

E U R i l l i m o n s	2 0 1 0	Q 1 2 0 1 1	G i d 2 0 1 1 a n c e u
R e e n e s v u	8 7 0	4 8 6	1 0 5 1 1 0 –
T l O i E t t o a p e r a n g x p e n s e s	7 7 4	1 9 9
h i I O O t t e r p e r a n g n c o m e	0 2.	0 1.
f i f i P O t t r o r o m p e r a o n s	9 8	2 8 8	1 0 1 3 –

Investment in Proprietary R&D will amount to EUR 40-45 million (2010: EUR 26.3 million)

S B l h a a n c e	t e e		S h h a r e o	l d i n
E U R i l l io m ns	M M h 3 3 1, 1 a r c 2 0 1 1	D D 3 3 1 1, e c. 2 0 1 0
A t s s e s			T S k t r e a s r o c u y
C C h, h E i l & t a s a s q u v a e n s S M k b l i i t t a r e a e e c u r e s	1 1 9. 8	1 0 8. 4	0 0. 4 4 % % M & t a n a g e m e n	U i d i f i t n e n
O C h A t t t e r u r r e n s s e s	4 9 7.	2 4. 1	S i p e r s o r u v y B d o a r	1 7 %
T l N C A t t t o a o n- r r e n s s e s u	7 9. 0	8 0. 0	2 % N i t o v a r	s
T l A t t o a s s e s	2 4 6. 7	2 1 2. 6	6 4 %
L i b i l i i t a e s
C T l L i b i l i i t t t o a u r r e n a e s	3 0. 3	2 1. 4		R i l t
C C T l N N L i b i l i i t t t t o a o o n n- r r r r e e n n a e s u u	1 0. 6	3 5.		e a 2 8 %
T l S h h l d ' E i t t o a a r e o e r s q u y	2 0 5. 8	1 8 5. 9
T l L i b i l i i t t o a a e s	2 4 6. 7	2 1 2. 6

Shares issued: 22,890,252 (Dec 31, 2010)

Management Team

Dr. Simon E. Moroney, CEO

• Co-founder; prior positions: University of Cambridge/UK, University of British Columbia/Canada, ETH Zurich/CH, I Gmmuno en I A i t i th H d M di l S h l B t /USA Inc., Associate in the Harvard Medical School, Boston/USA
• Commonwealth Scholar to the University of Oxford – D. Phil. 1984
• German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding Services to the Bavarian Economy (2009)

Jens Holstein CFOHolstein,

• Joined MorphoSys in 2011 from Fresenius Kabi
• Prior positions: Regional CFO for the region EME of Fresenius Kabi AG; variety of financial and general management positions at Fresenius
• Prior to joining Fresenius Mr Holstein spent several years in the consulting industry (Frankfurt and London) Fresenius, Mr. Holstein consulting (Frankfurt
• Mr. Holstein holds a Diploma in Business Administration from University of Münster.

Dr. Arndt Schottelius, CDO

• Joined MorphoSys in 2008 from Genentech Inc., SF, position: Medical Director, Immunology Development
• Prior positions: Berlex Biosciences, USA; Schering, Germany; Charité University Hospital, Berlin
• PhD and MD degrees from the Albert-Ludwigs-University, Freiburg/Germany
• Medical studies in Germany, UK and Switzerland

D M li S ll CSODr. Marlies Sproll,

• Joined MorphoSys in 2000 as R&D department head, promoted to CSO in 2005
• Prior positions: Vienna research facility of Boehringer Ingelheim, lab leader at Merck KGaA in Darmstadt/ Germany, involved in preclinical development of therapeutic antibodies
• Ph D f th M Pl k I tit t i Tübi /G D t f N t l S i b th U i it f St tt t Ph.D. from the Max PlanckInstitute in Tübingen/Germany, Doctor of Natural Science by the University of Stuttgart

A Rich Potential Newsflow in 2011

• US patent granted on MOR103 ⁹
• Double digit EUR million technology milestone received from Novartis technology received ⁹
• MOR202
  • Publish MOR202 pre-clinical data at ASCO
  • Start Phase 1 study in multiple myeloma patients
• MOR103
• Complete enrollment of Phase 1b/2a rheumatoid arthritis study
• Start Phase 1b in multiple sclerosis patients
• 1–3 partner INDs 3 (⁹)
• Data from ongoing trials of partnered programs

• First diagnostic kit based on ^a HuCAL antibody will be launched kit HuCAL antibody will be ⁹

• Further technology announcements

• New deal(s) based on Slonomics technology

Thank You

www.morphosys.com

Dr. Claudia Gutjahr-Löser

Head of Corporate Comm. & IR

Phone +49 ( ) 0 89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email investors@morphosys.com